Sunitinib clinical trials
Also written Sutent, SU011248 and SU11248.
Includes 1 study of Sunitinib maleate.
How each study uses Sunitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Sunitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Jan 2006 · SUTENT · NDA 021938 (FDA, Drugs@FDA)
- European Union
- 19 Jul 2006 · Sutent · EMEA/H/C/000687 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
323 studies that test it; most in 2007 (71)
| Year | Studies |
|---|---|
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 13 |
| 2006 | 41 |
| 2007 | 71 |
| 2008 | 49 |
| 2009 | 38 |
| 2010 | 18 |
| 2011 | 10 |
| 2012 | 13 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 8 |
| 2017 | 10 |
| 2018 | 6 |
| 2019 | 7 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 76 · Other 247
Pfizer (58) · National Cancer Institute (NCI) (39) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (9) · Amsterdam UMC, location VUmc (6) · Case Comprehensive Cancer Center (6) · Massachusetts General Hospital (6) · University Health Network, Toronto (5)
Often tested with
Tested in the same studies.
Erlotinib (10) · Gemcitabine (10) · Cisplatin (9) · Sorafenib (7) · Pazopanib (7) · Bevacizumab (7) · Capecitabine (7) · Crizotinib (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 12 phase 3 studies under way
Sunitinib is the comparator. A study of two new drugs counts under both.
- 2Savolitinib · AstraZeneca
- 2Benmelstobart · Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · next primary completion Jun 2027
- 2Ripretinib · Deciphera Pharmaceuticals, LLC · next primary completion Dec 2027
- 2Everolimus · Eisai Inc., Peking University Cancer Hospital & Institute · next primary completion Dec 2028
- 1Atezolizumab · Hoffmann-La Roche · next primary completion Jul 2028
- 1Niraparib · Hoffmann-La Roche · next primary completion Jul 2028
- 1Cabozantinib · Hoffmann-La Roche · next primary completion Jul 2028
- 1Durvalumab · AstraZeneca
Reaching primary completion within a year · 8
Studies that test Sunitinib.
- Dec 2026A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Phase 1 · Taiho Pharmaceutical Co., Ltd.
- Dec 2026Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)Phase 2 · M.D. Anderson Cancer Center
- Dec 2026Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsPhase 1 · National Cancer Institute (NCI)
- Dec 2026ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTPhase 2 · University of Miami
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Jul 2027Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaPhase 2 · M.D. Anderson Cancer Center
- Aug 2027Losartan + Sunitinib in Treatment of OsteosarcomaPhase 1 · University of Colorado, Denver
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses Sunitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 323
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as SunitinibHow we know
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingPhase 2University of MiamiNCT05366816Written as SunitinibHow we know
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687123Written as Sunitinib MalateHow we know
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Sunitinib (CLOSED TO ENROLLMENT)How we know
- Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingPhase 1University of Colorado, DenverNCT03900793Written as SunitinibHow we know
- Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCCRecruitingPhase 1/2State University of New York at BuffaloNCT06222593Written as Bicalutamide in combination with SunitinibHow we know
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as SunitinibHow we know
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as SunitinibHow we know
- Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingPhase 1/2Rabin Medical CenterNCT06940349Written as SunitinibHow we know
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as SunitinibHow we know
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingPhase 4University Medical Center GroningenNCT05949424Written as SunitinibHow we know
- Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNot applicableFirst Affiliated Hospital, Sun Yat-Sen UniversityNCT06032728Written as SunitinibHow we know
- A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNot applicableFirst Affiliated Hospital, Sun Yat-Sen UniversityNCT02688491Written as sunitinibHow we know
- A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)TerminatedPhase 2Genentech, Inc.NCT00434226Written as sunitinibHow we know
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Sunitinib MalateHow we know
- Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT02068586Written as SunitinibHow we know
- Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)TerminatedPhase 2Association of Urologic Oncology (AUO)NCT01216371Written as SunitinibHow we know
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT01396408Written as SunitinibHow we know
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingPhase 2Dwight OwenNCT03463460Written as Sunitinib MalateHow we know
- Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390826Written as SunitinibHow we know
See all 323 studies that test Sunitinib →
Given beside what is tested · 45 — Sunitinib is usual care or a partner of the new treatment
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingPhase 3Cogent Biosciences, Inc.NCT05208047Written as SunitinibHow we know
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedPhase 3Bristol-Myers SquibbNCT02231749Written as SunitinibHow we know
- Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT01391962Written as SunitinibHow we know
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GISTActive, not recruitingPhase 2Sarcoma Alliance for Research through CollaborationNCT06208748Written as Bezuclastinib in combination with sunitinibHow we know
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedPhase 1/2Cogent Biosciences, Inc.NCT02401815Written as SunitinibHow we know
- Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompletedPhase 2M.D. Anderson Cancer CenterNCT01254864Written as SunitinibHow we know
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedPhase 1/2Grupo Espanol de Investigacion en SarcomasNCT03277924Written as Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]How we know
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as SunitinibHow we know
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT02483247Written as SunitinibHow we know
- Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell CarcinomaTerminatedPhase 1Ludwig Institute for Cancer ResearchNCT00520533Written as Sunitinib malateHow we know
- Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)CompletedPhase 2MendusNCT02432846Written as SunitinibHow we know
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01664182Written as Sunitinib MalateHow we know
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedPhase 1Bristol-Myers SquibbNCT01472081Written as SunitinibHow we know
- A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT02402062Written as TH-302 + SunitinibHow we know
- AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedPhase 2AmgenNCT00853372Written as SunitinibHow we know
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Sunitinib MalateHow we know
- Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast CancerTerminatedPhase 1/2University of California, San FranciscoNCT00616122Written as sunitinib malateHow we know
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell CarcinomaCompletedPhase 2Hoffmann-La RocheNCT01984242Written as SunitinibHow we know
- A Study for Participants With Metastatic Renal Cell CarcinomaCompletedPhase 2Eli Lilly and CompanyNCT00709995Written as SunitinibHow we know
- A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell CarcinomaTerminatedPhase 2Eli Lilly and CompanyNCT01391130Written as SunitinibHow we know
Showing 20 of 45.
As the comparator · 39 — what is tested is compared with Sunitinib
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as SunitinibHow we know
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyRecruitingPhase 3GlaxoSmithKlineNCT07218926Written as SunitinibHow we know
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingPhase 1/23D Medicines (Sichuan) Co., Ltd.NCT05024214Written as SunitinibHow we know
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingPhase 3Peking University Cancer Hospital & InstituteNCT07165418Written as SunitinibHow we know
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as SunitinibHow we know
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingPhase 3AstraZenecaNCT05043090Written as sunitinibHow we know
- Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 3Sun Yat-sen UniversityNCT07881900Written as SunitinibHow we know
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingPhase 3Deciphera Pharmaceuticals, LLCNCT03673501Written as SunitinibHow we know
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as SunitinibHow we know
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT03141177Written as SunitinibHow we know
- Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 3ExelixisNCT05678673Written as Sunitinib MalateHow we know
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingPhase 3AstraZenecaNCT03091192Written as SunitinibHow we know
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894Written as SunitinibHow we know
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedPhase 2Zai Lab (Shanghai) Co., Ltd.NCT04633122Written as SunitinibHow we know
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingPhase 3Eisai Inc.NCT02811861Written as SunitinibHow we know
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedPhase 3Merck Sharp & Dohme LLCNCT02853331Written as SunitinibHow we know
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingPhase 3Deciphera Pharmaceuticals, LLCNCT05734105Written as SunitinibHow we know
- Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT04394975Written as sunitinibHow we know
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedPhase 3PfizerNCT02684006Written as SunitinibHow we know
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT02230176Written as SunitinibHow we know
Showing 20 of 39.
Codes
What other systems call Sunitinib · ClinicalTrials.gg INT006665
- MeSH (NLM) D000077210SunitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V99T50803MSUNITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 357977Confirmed FDA, Wikidata
- Wikidata Q417542sunitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71622SunitinibOne source FDA
- DrugBank DB01268One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077210 | Sunitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V99T50803M | SUNITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 357977 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417542 | sunitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71622 | Sunitinib | One source FDA |
| DrugBank | DB01268 | — | One source Wikidata |
Also registered as sunitinib malate (UNII LVX8N1UT73 · RxNorm 616275).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.